✦ LIBER ✦

Thymus, Thymoma, and Specific T Cells in Myasthenia Gravis

✍ Scribed by D. BEESON; A. P. BOND; L. CORLETT; S. J. CURNOW; M. E. HILL; L. W. JACOBSON; C. MACLENNAN; A. MEAGER; A-M. MOODY; P. MOSS; N. NAGVEKAR; J. NEWSOM-DAVIS; N. PANTIC; I. ROXANIS; E.G. SPACK; A. VINCENT; N. WILLCOX

Book ID: 111394724
Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 741 KB
Volume: 841
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.1998.tb10950.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The thymus, thymoma and myasthenia gravi

The thymus, thymoma and myasthenia gravis

✍ Fujii, Yoshitaka 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 251 KB

Antigen-specific T-cell activation in hy

Antigen-specific T-cell activation in hyperplastic thymus in myasthenia gravis

✍ Kimiaki Utsugisawa; Yuriko Nagane; Shigeaki Suzuki; Ryushi Kondoh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Myasthenia gravis patients with thymus h

Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations

✍ Anne Spurkland; Nils Erik Gilhus; Kjersti S. Rønningen; John A. Aarli; Froda Var 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

Characterization of specific T cells in

Characterization of specific T cells in myasthenia gravis

✍ Angela Vincent; Nick Willcox 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 199 KB

Thymus cells in myasthenia gravis: a two

Thymus cells in myasthenia gravis: a two-colour flow cytometric analysis of lymphocytes in the thymus and thymoma

✍ Yoshitaka Fujii; Masanobu Hayakawa; Kazuya Nakahara 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 656 KB

Chemotherapy in thymoma and myasthenia g

Chemotherapy in thymoma and myasthenia gravis

✍ P. A. Kosmidis; E. Iliopoulos; S. Pentea 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 519 KB

Malignant thymoma (MT) is a rare tumor that is often associated with myasthenia gravis (MG). This tumor is considered resistant to chemotherapy. We had the opportunity to treat five patients with MT with cyclophosphamide 800 mg/m2, Adriamycin 50 mg/m2, and vincristine 1.4 mg/m2 (CAV) in cycles of 21